People often get immunotherapy as a treatment for cancer. These immunotherapy treatments can be effective, but they may cause your immune system to have an unnatural response. Your body, as a result ...

INCHEON, South Korea, Aug. 6, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) ...

This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...

Credit: Celltrion CRS is a life-threatening condition that results in the excessive release of cytokines into the bloodstream, causing inflammation and damage to organs and tissues. With the newly ...

The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

China: CAR T-cell therapy, already in use for certain B-cell–driven autoimmune diseases such as lupus, has now demonstrated ...

The transition from preclinical development to clinical trials is a critical, yet high-risk stage in drug development, with approximately 89% of drugs failing to progress through all phases of ...

An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as monotherapy and in combination with rituximab among patients with B-cell lymphomas, ...

With the newly approved indication for CRS, Avtozma IV now aligns with all approved indications for Actemra IV. CRS is a life-threatening condition in which an overactive immune response leads to the ...